These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7681508)

  • 1. Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
    Martin U; Sponer G; Strein K
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):455-61. PubMed ID: 7681508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U; Fischer S; Sponer G
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant tissue-type plasminogen activator on life-threatening acute pulmonary thromboembolism in a canine model: a comparative study of e6010 and alteplase.
    Tagami H; Utoh J; Sun LB; Okamoto K; Moriyama S; Kunitomo R; Kitamura N
    Ann Thorac Cardiovasc Surg; 2000 Oct; 6(5):299-303. PubMed ID: 11173335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
    Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J
    Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.
    Tebbe U; Graf A; Kamke W; Zahn R; Forycki F; Kratzsch G; Berg G
    Am Heart J; 1999 Jul; 138(1 Pt 1):39-44. PubMed ID: 10385761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
    Meyer G; Sors H; Charbonnier B; Kasper W; Bassand JP; Kerr IH; Lesaffre E; Vanhove P; Verstraete M
    J Am Coll Cardiol; 1992 Feb; 19(2):239-45. PubMed ID: 1732347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
    Meneveau N; Schiele F; Vuillemenot A; Valette B; Grollier G; Bernard Y; Bassand JP
    Eur Heart J; 1997 Jul; 18(7):1141-8. PubMed ID: 9243149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
    Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML
    J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
    Prewitt RM; Hoy C; Kong A; Gu SA; Greenberg D; Cook R; Chan SM; Ducas J
    Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fibrinolytic agents--who benefits when?].
    Weichert W; Seifried E
    Ther Umsch; 1995 Oct; 52(10):652-60. PubMed ID: 7482376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.
    Shiffman F; Ducas J; Hollett P; Israels E; Greenberg D; Cook R; Prewitt RM
    Circulation; 1988 Jul; 78(1):214-20. PubMed ID: 3133136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.